Table 2: Effects of tulobuterol and PDW on pulmonary function, quality of life, and hs-CRP.

 Variables

Tulobuterol (n = 13)

PDW (n = 10)

Pre

Post

Pre

Post

Pulmonary function

FVC (l)

2.29 ± 0.60

2.38 ± 0.50

2.30 ± 0.50

2.40 ± 0.47*

FEV1 (l)

1.48 ± 0.38

1.53 ± 0.35

1.46 ± 0.34

1.56 ± 0.32*

FEV1 %pred (%)

82.07 ± 17.3

86.05 ± 14.2

80.49 ± 14.3

86.00 ± 11.6*

PEF (l/s)

4.05 ± 1.53

4.30 ± 1.41

3.93 ± 1.57

4.56 ± 1.64*

MEF50 (l/s)

1.23 ± 0.42

1.42 ± 0.62

1.22 ± 0.44

1.36 ± 0.44*

MEF25 (l/s)

0.40 ± 0.13

0.41 ± 0.15

0.39 ± 0.14

0.43 ± 0.14*

SGRQ domain scores

Symptoms

54.30 ± 22.48

54.16 ± 20.40

47.07 ± 21.59

51.58 ± 24.02

Activity

42.38 ± 24.43

48.83 ± 25.46*

41.22 ± 20.81

52.85 ± 21.98*

Impacts

23.89 ± 16.04

25.56 ± 15.32

23.54 ± 13.95

25.51 ± 16.27

Total

35.72 ± 17.93

37.71 ± 16.57

33.98 ± 15.94

37.71 ± 16.79

Hs-CRP (ng/ml)

1279 ± 2713

2521 ± 7986

685 ± 697

839 ± 947

Abbreviations: FEV1: Forced Expiratory Volume in 1.0 s; FVC: Forced Vital Capacity; PEF: Peak Expiratory Flow; MEF50: Maximum Expiratory Flow at 50% of FVC; MEF25: Maximum Expiratory Flow at 25% of FVC; Hs-CRP: Hypersensitive-C-Reactive Protein.
Data are expressed as the mean ± SD.